Results 161 to 170 of about 1,844 (180)
Some of the next articles are maybe not open access.
Mavacamten for obstructive hypertrophic cardiomyopathy
PrescriberMavacamten (Camzyos) is a cardiac myosin inhibitor indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. This article discusses its efficacy, adverse effects and place in therapy.
openaire +1 more source
Mavacamten for hypertrophic cardiomyopathy: effectiveness and value.
Journal of managed care & specialty pharmacy, 2022DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions.
Molly, Beinfeld +6 more
openaire +1 more source
Evaluation of mavacamten in patients with hypertrophic cardiomyopathy
Journal of Cardiovascular MedicineAims We aimed to comprehensively assess the safety and efficacy of mavacamten in hypertrophic cardiomyopathy (HCM) patients. Methods A systematic review and meta-analysis was conducted, and efficacy [changes in postexercise left ventricular outflow tract (LVOT) gradient, left ...
Hui-Ling, Liao, Yi, Liang, Bo, Liang
openaire +2 more sources
Mavacamten: treatment aspirations in hypertrophic cardiomyopathy
The Lancet, 2020Michael, Papadakis +2 more
openaire +2 more sources
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients
Trends in Pharmacological Sciences, 2023Nicole Zatorski +2 more
openaire +2 more sources
Mavacamten en miocardiopatía hipertrófica obstructiva sintomática
Panorama Actual del MedicamentoMavacamten es un inhibidor selectivo, alostérico y reversible de la miosina cardiaca. Mavacamten modula el número de cabezas de miosina que pueden entrar en estados generadores de fuerza, reduciendo así la probabilidad de formación de puentes cruzados sistólicos productores de fuerza y diastólicos residuales.
openaire +1 more source
Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China
JAMA Cardiology, 2023openaire +2 more sources
MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY: EFFECTIVE, BUT AFFORDABLE?
Journal of the American College of Cardiology, 2023Shivani Hanchate +4 more
openaire +1 more source
ICER assessing mavacamten for hypertrophic cardiomyopathy
PharmacoEconomics & Outcomes News, 2021openaire +1 more source